Cargando…

Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel

In most diagnostic laboratories, targeted next-generation sequencing (NGS) is currently the default assay for the detection of somatic variants in solid as well as haematological tumours. Independent of the method, the final outcome is a list of variants that differ from the human genome reference s...

Descripción completa

Detalles Bibliográficos
Autores principales: Froyen, Guy, Le Mercier, Marie, Lierman, Els, Vandepoele, Karl, Nollet, Friedel, Boone, Elke, Van der Meulen, Joni, Jacobs, Koen, Lambin, Suzan, Vander Borght, Sara, Van Valckenborgh, Els, Antoniou, Aline, Hébrant, Aline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966529/
https://www.ncbi.nlm.nih.gov/pubmed/31888289
http://dx.doi.org/10.3390/cancers11122030
_version_ 1783488754851250176
author Froyen, Guy
Le Mercier, Marie
Lierman, Els
Vandepoele, Karl
Nollet, Friedel
Boone, Elke
Van der Meulen, Joni
Jacobs, Koen
Lambin, Suzan
Vander Borght, Sara
Van Valckenborgh, Els
Antoniou, Aline
Hébrant, Aline
author_facet Froyen, Guy
Le Mercier, Marie
Lierman, Els
Vandepoele, Karl
Nollet, Friedel
Boone, Elke
Van der Meulen, Joni
Jacobs, Koen
Lambin, Suzan
Vander Borght, Sara
Van Valckenborgh, Els
Antoniou, Aline
Hébrant, Aline
author_sort Froyen, Guy
collection PubMed
description In most diagnostic laboratories, targeted next-generation sequencing (NGS) is currently the default assay for the detection of somatic variants in solid as well as haematological tumours. Independent of the method, the final outcome is a list of variants that differ from the human genome reference sequence of which some may relate to the establishment of the tumour in the patient. A critical point towards a uniform patient management is the assignment of the biological contribution of each variant to the malignancy and its subsequent clinical impact in a specific malignancy. These so-called biological and clinical classifications of somatic variants are currently not standardized and are vastly dependent on the subjective analysis of each laboratory. This subjectivity can thus result in a different classification and subsequent clinical interpretation of the same variant. Therefore, the ComPerMed panel of Belgian experts in cancer diagnostics set up a working group with the goal to harmonize the biological classification and clinical interpretation of somatic variants detected by NGS. This effort resulted in the establishment of a uniform, two-level classification workflow system that should enable high consistency in diagnosis, prognosis, treatment and follow-up of cancer patients. Variants are first classified into a tumour-independent biological five class system and subsequently in a four tier ACMG clinical classification. Here, we describe the ComPerMed workflow in detail including examples for each step of the pipeline. Moreover, this workflow can be implemented in variant classification software tools enabling automatic reporting of NGS data, independent of panel, method or analysis software.
format Online
Article
Text
id pubmed-6966529
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69665292020-01-27 Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel Froyen, Guy Le Mercier, Marie Lierman, Els Vandepoele, Karl Nollet, Friedel Boone, Elke Van der Meulen, Joni Jacobs, Koen Lambin, Suzan Vander Borght, Sara Van Valckenborgh, Els Antoniou, Aline Hébrant, Aline Cancers (Basel) Project Report In most diagnostic laboratories, targeted next-generation sequencing (NGS) is currently the default assay for the detection of somatic variants in solid as well as haematological tumours. Independent of the method, the final outcome is a list of variants that differ from the human genome reference sequence of which some may relate to the establishment of the tumour in the patient. A critical point towards a uniform patient management is the assignment of the biological contribution of each variant to the malignancy and its subsequent clinical impact in a specific malignancy. These so-called biological and clinical classifications of somatic variants are currently not standardized and are vastly dependent on the subjective analysis of each laboratory. This subjectivity can thus result in a different classification and subsequent clinical interpretation of the same variant. Therefore, the ComPerMed panel of Belgian experts in cancer diagnostics set up a working group with the goal to harmonize the biological classification and clinical interpretation of somatic variants detected by NGS. This effort resulted in the establishment of a uniform, two-level classification workflow system that should enable high consistency in diagnosis, prognosis, treatment and follow-up of cancer patients. Variants are first classified into a tumour-independent biological five class system and subsequently in a four tier ACMG clinical classification. Here, we describe the ComPerMed workflow in detail including examples for each step of the pipeline. Moreover, this workflow can be implemented in variant classification software tools enabling automatic reporting of NGS data, independent of panel, method or analysis software. MDPI 2019-12-16 /pmc/articles/PMC6966529/ /pubmed/31888289 http://dx.doi.org/10.3390/cancers11122030 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Project Report
Froyen, Guy
Le Mercier, Marie
Lierman, Els
Vandepoele, Karl
Nollet, Friedel
Boone, Elke
Van der Meulen, Joni
Jacobs, Koen
Lambin, Suzan
Vander Borght, Sara
Van Valckenborgh, Els
Antoniou, Aline
Hébrant, Aline
Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel
title Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel
title_full Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel
title_fullStr Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel
title_full_unstemmed Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel
title_short Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel
title_sort standardization of somatic variant classifications in solid and haematological tumours by a two-level approach of biological and clinical classes: an initiative of the belgian compermed expert panel
topic Project Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966529/
https://www.ncbi.nlm.nih.gov/pubmed/31888289
http://dx.doi.org/10.3390/cancers11122030
work_keys_str_mv AT froyenguy standardizationofsomaticvariantclassificationsinsolidandhaematologicaltumoursbyatwolevelapproachofbiologicalandclinicalclassesaninitiativeofthebelgiancompermedexpertpanel
AT lemerciermarie standardizationofsomaticvariantclassificationsinsolidandhaematologicaltumoursbyatwolevelapproachofbiologicalandclinicalclassesaninitiativeofthebelgiancompermedexpertpanel
AT liermanels standardizationofsomaticvariantclassificationsinsolidandhaematologicaltumoursbyatwolevelapproachofbiologicalandclinicalclassesaninitiativeofthebelgiancompermedexpertpanel
AT vandepoelekarl standardizationofsomaticvariantclassificationsinsolidandhaematologicaltumoursbyatwolevelapproachofbiologicalandclinicalclassesaninitiativeofthebelgiancompermedexpertpanel
AT nolletfriedel standardizationofsomaticvariantclassificationsinsolidandhaematologicaltumoursbyatwolevelapproachofbiologicalandclinicalclassesaninitiativeofthebelgiancompermedexpertpanel
AT booneelke standardizationofsomaticvariantclassificationsinsolidandhaematologicaltumoursbyatwolevelapproachofbiologicalandclinicalclassesaninitiativeofthebelgiancompermedexpertpanel
AT vandermeulenjoni standardizationofsomaticvariantclassificationsinsolidandhaematologicaltumoursbyatwolevelapproachofbiologicalandclinicalclassesaninitiativeofthebelgiancompermedexpertpanel
AT jacobskoen standardizationofsomaticvariantclassificationsinsolidandhaematologicaltumoursbyatwolevelapproachofbiologicalandclinicalclassesaninitiativeofthebelgiancompermedexpertpanel
AT lambinsuzan standardizationofsomaticvariantclassificationsinsolidandhaematologicaltumoursbyatwolevelapproachofbiologicalandclinicalclassesaninitiativeofthebelgiancompermedexpertpanel
AT vanderborghtsara standardizationofsomaticvariantclassificationsinsolidandhaematologicaltumoursbyatwolevelapproachofbiologicalandclinicalclassesaninitiativeofthebelgiancompermedexpertpanel
AT vanvalckenborghels standardizationofsomaticvariantclassificationsinsolidandhaematologicaltumoursbyatwolevelapproachofbiologicalandclinicalclassesaninitiativeofthebelgiancompermedexpertpanel
AT antonioualine standardizationofsomaticvariantclassificationsinsolidandhaematologicaltumoursbyatwolevelapproachofbiologicalandclinicalclassesaninitiativeofthebelgiancompermedexpertpanel
AT hebrantaline standardizationofsomaticvariantclassificationsinsolidandhaematologicaltumoursbyatwolevelapproachofbiologicalandclinicalclassesaninitiativeofthebelgiancompermedexpertpanel